Calamos Advisors LLC Grows Stake in Artivion, Inc. (NYSE:AORT)

Calamos Advisors LLC boosted its stake in Artivion, Inc. (NYSE:AORT) by 113.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 63,029 shares of the company’s stock after buying an additional 33,541 shares during the quarter. Calamos Advisors LLC’s holdings in Artivion were worth $1,802,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Quarry LP raised its holdings in shares of Artivion by 210.8% during the third quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after acquiring an additional 820 shares during the last quarter. R Squared Ltd purchased a new stake in shares of Artivion during the fourth quarter worth approximately $39,000. GAMMA Investing LLC increased its position in shares of Artivion by 21.8% during the fourth quarter. GAMMA Investing LLC now owns 2,772 shares of the company’s stock worth $79,000 after purchasing an additional 497 shares in the last quarter. KBC Group NV raised its stake in Artivion by 80.4% in the 4th quarter. KBC Group NV now owns 2,813 shares of the company’s stock valued at $80,000 after purchasing an additional 1,254 shares during the last quarter. Finally, RiverPark Advisors LLC lifted its holdings in Artivion by 151.6% in the 3rd quarter. RiverPark Advisors LLC now owns 5,387 shares of the company’s stock valued at $143,000 after purchasing an additional 3,246 shares in the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AORT has been the subject of a number of research reports. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Oppenheimer increased their price objective on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Finally, Needham & Company LLC restated a “buy” rating and set a $34.00 target price on shares of Artivion in a report on Tuesday, January 28th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $31.80.

Insider Buying and Selling at Artivion

In other news, SVP Jean F. Holloway sold 8,070 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total value of $243,068.40. Following the transaction, the senior vice president now owns 153,862 shares of the company’s stock, valued at $4,634,323.44. This represents a 4.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Amy Horton sold 4,329 shares of the stock in a transaction on Friday, December 6th. The stock was sold at an average price of $29.66, for a total value of $128,398.14. Following the transaction, the chief accounting officer now owns 135,660 shares of the company’s stock, valued at approximately $4,023,675.60. This represents a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,017 shares of company stock worth $600,007 in the last ninety days. 8.10% of the stock is owned by insiders.

Artivion Trading Up 1.0 %

Shares of AORT opened at $30.91 on Wednesday. Artivion, Inc. has a 12-month low of $16.48 and a 12-month high of $32.33. The firm has a market capitalization of $1.30 billion, a P/E ratio of -1,545.30 and a beta of 1.75. The firm has a 50-day moving average price of $29.61 and a 200 day moving average price of $27.51. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.